SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--The Institute for OneWorld Health, a US-based non-profit pharmaceutical company, today announced that Phase 3 research related to its first approved drug product, Paromomycin IM Injection (Paromomycin), was published in the current issue of The New England Journal of Medicine (NEJM). This clinical trial shows that the medicine paromomycin is safe, effective, and well suited to curing visceral leishmaniasis (VL), the world’s second most deadly parasitic disease after malaria.
